KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Other Non-Current Assets for 14 consecutive years, with $63.6 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets fell 13.91% year-over-year to $63.6 million; the TTM value through Mar 2026 reached $63.6 million, down 13.91%, while the annual FY2025 figure was $59.5 million, 8.96% down from the prior year.
  • Other Non-Current Assets hit $63.6 million in Q1 2026 for Alnylam Pharmaceuticals, up from $59.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $92.7 million in Q2 2023 and bottomed at $55.8 million in Q3 2025.
  • Average Other Non-Current Assets over 5 years is $68.2 million, with a median of $66.1 million recorded in 2022.
  • Year-over-year, Other Non-Current Assets soared 123.4% in 2022 and then dropped 28.06% in 2025.
  • Alnylam Pharmaceuticals' Other Non-Current Assets stood at $66.1 million in 2022, then dropped by 6.34% to $61.9 million in 2023, then increased by 5.51% to $65.3 million in 2024, then decreased by 8.96% to $59.5 million in 2025, then increased by 6.88% to $63.6 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $63.6 million, $59.5 million, and $55.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.